| Literature DB >> 26292218 |
Thanos Tsaktanis1, Heidi Kremling1, Miha Pavšič2, Ricarda von Stackelberg1, Brigitte Mack1, Akio Fukumori3, Harald Steiner4, Franziska Vielmuth5, Volker Spindler5, Zhe Huang1, Jasmine Jakubowski6, Nikolas H Stoecklein7, Elke Luxenburger1, Kirsten Lauber8, Brigita Lenarčič2, Olivier Gires9.
Abstract
Human epithelial cell adhesion molecule (HEPCAM) is a tumor-associated antigen frequently expressed in carcinomas, which promotes proliferation after regulated intramembrane proteolysis. Here, we describe extracellular shedding of HEPCAM at two α-sites through a disintegrin and metalloprotease (ADAM) and at one β-site through BACE1. Transmembrane cleavage by γ-secretase occurs at three γ-sites to generate extracellular Aβ-like fragments and at two ϵ-sites to release human EPCAM intracellular domain HEPICD, which is efficiently degraded by the proteasome. Mapping of cleavage sites onto three-dimensional structures of HEPEX cis-dimer predicted conditional availability of α- and β-sites. Endocytosis of HEPCAM warrants acidification in cytoplasmic vesicles to dissociate protein cis-dimers required for cleavage by BACE1 at low pH values. Intramembrane cleavage sites are accessible and not part of the structurally important transmembrane helix dimer crossing region. Surprisingly, neither chemical inhibition of cleavage nor cellular knock-out of HEPCAM using CRISPR-Cas9 technology impacted the adhesion of carcinoma cell lines. Hence, a direct function of HEPCAM as an adhesion molecule in carcinoma cells is not supported and appears to be questionable.Entities:
Keywords: ADAM; cell adhesion; epithelial cell adhesion molecule (EPCAM); proteolysis; β-secretase 1 (BACE1)
Mesh:
Substances:
Year: 2015 PMID: 26292218 PMCID: PMC4591836 DOI: 10.1074/jbc.M115.662700
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157